Anti rsk2

Antibodies anti-HA (Babco), anti-RSK2, anti-APPL1, anti-Rab7, anti-TrkB (Santa Cruz Bio-technology), anti-PLD1, anti-ERK, anti-phospho-ERK, (New England BioLabs), anti-β-tubulin, anti-CREB (Millipore), anti-GAPDH, anti-phospho-CREB (Ser-133), anti-mTOR, anti-phospho-mTOR (Ser-2481), anti-phospho-S6K (Thr-389), anti-phospho-S6K (Thr-421/Ser-424), anti-PEA15 (Cell Signalling), anti-Rab5 (Transduction Laboratories) were used. Plasmids have been described previously15 (link)17 (link). ON-TARGETplus siRNA were obtained from Darmacon and BDNF was from Invitrogen.

NIH3T3 cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). H-Ras-transformed NIH3T3 cells were generated in-house and was described previously^{40 (link),41 (link)}. Human colon cancer cell line DLD-1, glioblastoma cell line SNB-75, and breast cancer cell lines Hs 578 T and MDA MB 231 were obtained from ATCC and were authenticated by STR DNA analysis (SickKids, Toronto). All cells were maintained in high glucose Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Ontario, Canada), supplemented with 10% fetal bovine serum (FBS) and antibiotic–antimycotic mixture (Invitrogen) (100 units/mL penicillin G sodium) at 37 °C and 5% CO₂.
U0126 was purchased from Cell Signaling Technology (Danvers, MA); 5-Aminolevulinic acid from Sigma (Oakville, ON); HIF-1α inhibitor (methyl 3-[[2-[4-(2-adamantyl)phenoxy]acetyl]amino]-4-hydroxybenzoate) from Santa Cruz Biotechnology (Dallas, TX); ABCB1 inhibitor, zosuquidar from Selleckchem, and pan-RSK inhibitor, SL0101 from Calbiochem (Darmstadt, Germany). Anti-phospho-ERK-1/2 and anti-phospho RSK antibodies were purchased from Cell Signaling (Danvers, MA), anti-ABCB1 antibody from Alomone Labs (Israel), anti-FECH, anti-phospho-S6, anti-RSK2, anti-total ERK antibodies, and the FITC-tagged Anti-ABCB1 antibody from Santa Cruz Biotechnology; anti-HIF-1α antibody, and anti-GAPDH antibody were purchased from Abcam (US).